Guildford, UK, 15 August 2013: ReNeuron announces that its Annual Report
and Accounts for the year ended 31 March 2013 and the Notice of the 2013 Annual General
Meeting (“AGM”) have been sent to shareholders and are available on the Company’s
ReNeuron’s AGM will be held at 10.00am on 13 September 2013 at the offices of Covington &
Burling LLP, 265 Strand, London, WC2R 1BH.
ReNeuron +44 (0) 1483 302560
Michael Hunt, Chief Executive Officer
Pat Huggins, Head of Finance
Buchanan +44 (0) 20 7466 5000
Mark Court, Fiona Henson, Sophie Cowles
Cenkos Securities +44 (0) 20 7397 8900
Stephen Keys, Adrian Hargrave (NOMAD and Broker)
Andy Roberts (Sales)
ReNeuron is a leading, clinical-stage stem cell business. Its primary objective is the development of
novel stem cell therapies targeting areas of significant unmet or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant
disease conditions where the cells can be readily administered “off-the-shelf” to any eligible patient
without the need for additional immunosuppressive drug treatments. ReNeuron’s lead candidate is
its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke.
This therapy is currently in clinical development. The Company is also developing stem cell therapies
for other conditions such as critical limb ischaemia, a serious and common side-effect of diabetes,
and blindness-causing diseases of the retina such as retinitis pigmentosa.
ReNeuron has also developed a range of stem cell lines for non-therapeutic applications – its
ReNcell® products for use in academic and commercial research. The Company’s ReNcell®CX and
ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Merck Millipore.
ReNeuron’s shares are traded on the London AIM market under the symbol RENE.L. Further
information on ReNeuron and its products can be found at www.reneuron.com.